Taro Pharmaceutical Industries Executives
Taro Pharmaceutical employs about 24 people. The company is managed by 24 executives with a total tenure of roughly 168 years, averaging almost 7.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Taro Pharmaceutical's management performance can provide insight into the firm performance.
| Uday Baldota CEO Chief Executive Officer, Director |
| Abhay Gandhi Chairman Vice Chairman of the Board |
Taro |
Taro Pharmaceutical Management Team Effectiveness
Taro Pharmaceutical's management efficiency ratios could be used to measure how well Taro Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Taro Pharmaceutical Workforce Comparison
Taro Pharmaceutical Industries is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 41,601. Taro Pharmaceutical adds roughly 24.0 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of 0.09 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.06 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.06. Taro Pharmaceutical Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Taro Pharmaceutical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Taro Pharmaceutical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Taro Pharmaceutical insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Franklin Resources Inc over six months ago Acquisition by Franklin Resources Inc of 1000 shares of Taro Pharmaceutical at 8.0 subject to Rule 16b-3 | ||
Franklin Resources Inc over six months ago Acquisition by Franklin Resources Inc of 7720 shares of Taro Pharmaceutical at 9.75 subject to Rule 16b-3 | ||
Sun Pharmaceutical Industries Ltd over six months ago Disposition of 712500 shares by Sun Pharmaceutical Industries Ltd of Taro Pharmaceutical at 6.0 subject to Rule 16b-3 | ||
Franklin Resources Inc over six months ago Purchase by Franklin Resources Inc of 4500 shares of Taro Pharmaceutical |
Taro Pharmaceutical Notable Stakeholders
A Taro Pharmaceutical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Taro Pharmaceutical often face trade-offs trying to please all of them. Taro Pharmaceutical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Taro Pharmaceutical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Uday Baldota | Chief Executive Officer, Director | Profile | |
| Abhay Gandhi | Vice Chairman of the Board | Profile | |
| Dilip Shanghvi | Chairman of the Board | Profile | |
| Avi Avramoff | Global Vice President - Research & Development | Profile | |
| Chantal LeBlanc | Vice President - Head of Quality | Profile | |
| Itamar Karsenti | Vice President - Head of Operations, Haifa | Profile | |
| Richard Glaze | Vice President - Head of Information Technology | Profile | |
| William Coote | Vice President Treasurer | Profile | |
| Michele Visosky | Vice President - Head of Human Resources | Profile | |
| Ara Aprahamian | Vice President - Sales and Marketing | Profile | |
| Daphne Huang | Chief Financial Officer, Chief Accounting Officer, Vice President | Profile | |
| James Kedrowski | Director | Profile | |
| Sudhir Valia | Director | Profile | |
| Linda Benshoshan | Independent Director | Profile | |
| Dov Pekelman | Independent Director | Profile | |
| Erik JD | General VP | Profile | |
| Erik Zwicker | Vice President General Counsel, Secretary | Profile | |
| Robert Stein | Independent Director | Profile | |
| Jayesh Shah | Head of Procurement | Profile | |
| Roman Kaplan | Vice Manager | Profile | |
| Ori Gutwerg | Vice President - Head of US Generics Rx | Profile | |
| Vikash Agarwal | Vice President - Head of Business Development | Profile | |
| Itzik Baruch | Vice Services | Profile | |
| Victoria Chester | Vice President - Head of Quality | Profile |
Taro Pharmaceutical Workforce Analysis
Traditionally, organizations such as Taro Pharmaceutical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Taro Pharmaceutical within its industry.Taro Pharmaceutical Manpower Efficiency
Return on Taro Pharmaceutical Manpower
| Revenue Per Employee | 26.2M | |
| Revenue Per Executive | 26.2M | |
| Net Income Per Employee | 2.2M | |
| Net Income Per Executive | 2.2M | |
| Working Capital Per Employee | 39.6M | |
| Working Capital Per Executive | 39.6M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in Taro Stock
If you are still planning to invest in Taro Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taro Pharmaceutical's history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |